Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Acute Effects of Grape Seed Extract on Insulin Sensitivity and Oxidative Stress and Inflammation Markers. (GSE2)

26 juli 2021 uppdaterad av: Clinical Nutrition Research Center, Illinois Institute of Technology

Effect of Grape Seed Extract on Modulation of Oxidative Stress/ Inflammation/ Insulin Sensitivity Induced by High Fat-carbohydrate Meal in Healthy Human Subjects

The proposed study aims to investigate that consumption of grape seed extract (GSE) would improve antioxidant status and impaired insulin action following consumption of a pro-oxidative high carbohydrate, high fat (HCHF) meal in healthy human subjects.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This study is a single-center, double blind, placebo-controlled, randomized, 2-arm, 2-sequence, crossover study

A planned sample size of 15 will be recruited into the study. This study will require one initial screening, one pre-study visit, two 6-hour study visits. The study will take 2-5 weeks per subject to complete.

The initial screening visit will provide subjects an Institutional Review Board approved consent document and determine subject eligibility through BMI calculated from height and weight measurements, vital signs, fasting blood glucose test (finger prick), lipid profiles (3 ml blood sampling via a butterfly needle device) and completion of a questionnaire related to general eating, health, and exercise habits.

If subjects are willing and eligible to participate, a 3-day food record (2 weekdays and 1 weekend day) will be instructed at the initial screening visit and collected at the pre-study visit to assess subjects' usual dietary intake pattern. After reviewing food records, subjects will be instructed to avoid any grapes, grape products, berries, berry products throughout the study and strictly follow a limited polyphenolic diet for 3 days prior to each 6-hr study visit, while maintaining their usual diet pattern and physical activity. Prior to each study visit, subject will be advised to have the same or similar dinner meal to control the second meal effect from food and beverage intake of the night before each study visit.

Subjects will arrive at the center after ~10 hours overnight fasting, well hydrated and rested. Each study visit will require blood draws throughout the visit. After pre-study procedures (height, weight, waist circumferences, vital sign, and fasting blood glucose test), a registered nurse will place a catheter in subject's arm for the purpose of multiple blood sample collections and collect fasting blood sample. During each study visit, subject will take one of the two capsules right after fasting blood draw), based on randomization sequences (either 1 grape seed extract capsule or 1 placebo capsule). One hour after administration of the assigned capsule, blood samples will be collected. And a standard high carbohydrate and high fat breakfast meal will be served and subject will have blood draws at designated time up to 5 hours.

Studietyp

Interventionell

Inskrivning (Faktisk)

13

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Förenta staterna
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60616
        • Clinical Nutrition Research Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

20 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Aged between 20 to 65 years old
  • Body Mass Index (BMI) range from 18.5 to 24.9 kg/m2; exception BMI 18.5 to 23 kg/m2 for Asian population
  • Fasting blood glucose concentration < 110 mg/dL
  • Fasting LDL-cholesterol <180 mg/dL
  • Fasting Total cholesterol and Fasting Triglycerides < 250 mg/dL
  • Weight stable: not gained or lost weight +/- 5 lbs in previous 3 months
  • Non-smokers
  • No clinical evidence of cardiovascular, metabolic, respiratory, renal, gastrointestinal or hepatic disease
  • Not taking any medications or dietary supplements that would interfere with outcomes of the study, i.e. lipid lowering medications, anti-inflammatory drugs, fish oil, probiotics, grape seed supplement, etc…If anti-inflammation and/or antibiotic medications/supplements are taken, subjects may qualify if go off these medications/supplements 30 days wash-out before entering the study.
  • Able to provide informed consent
  • Able to comply and perform the procedures requested by the protocol

Exclusion Criteria:

  • Past smokers: abstinence for less than 2 years
  • Men and women who smoke
  • Men and women with known or suspected food intolerance, allergies or hypersensitivity to the study materials or closely related compound or any their stated ingredients.
  • Men and women known to have/diagnosed with diabetes mellitus
  • Men and women who have fasting blood glucose concentrations ≥110 mg/dL
  • Men and women who have uncontrolled blood pressure >140 mmHg/90 mmHg
  • Men and women with documented vascular disease, e.g., heart failure, myocardial infarction, stroke, angina, related surgeries.
  • Men and women with cancer other than non-melanoma skin cancer in previous 5 years.
  • Men and women who are taking medication or dietary supplements that may interfere with the outcomes of the study; e.g., antioxidant supplements, anti-inflammation, lipid lowering medication. Subjects may choose to go off dietary supplements (requires 30 days washout).
  • Men and women who are taking blood pressure lowering medication that may interfere the outcomes of the study; e.g. diuretics.
  • Men and women who have donated blood within 3 months of the screening visit and blood donors/participants for whom participation in this study will result in having donated more than 1500 milliliters of blood in the previous 12 months.
  • Men and women who are vegetarians or vegans
  • Substance (alcohol or drug) abuse within the last 2 years.
  • Excessive coffee and tea consumers (> 4 cups/day)
  • Men and women who do excessive exercise regularly or athlete
  • Unstable weight: gained or lost weight +/- 5 lbs in previous 3 months
  • Women who are known to be pregnant or who are intending to become pregnant over the course of the study
  • Women who are lactating

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Active Capsule
Grape Seed Extract Capsule: 300 mg
Kosttillskott: Active Capsule
GSE Capsule
Placebo-jämförare: Placebo Capsule
Placebo Capsule: Maltodextrin
Kosttillskott: Placebo Capsule
Placebo Capsule

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Changes in insulin and glucose concentrations over 6 hours after the Grape Seed Extract Capsule administration
Tidsram: 6 hours
The timing influence of the Grape Seed Extract administration on insulin and glucose concentrations in relative to the standard meal intake (1 hour before the meal and 5 hours after the meal)
6 hours

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Changes in oxidative stress markers and inflammatory markers over 6 hours after the Grape Seed Extract Capsule administration
Tidsram: 6 hours
The timing influence of grape seed extract administration on oxidative stress markers and inflammatory markers in relative to the standard meal intake (1 hour before the meal and 5 hours after the meal)
6 hours

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Clinical Nutrition Research Center, Illinois Institute of Technology

Utredare

  • Studiestol: Britt Burton-Freeman, Ph.D, MS, Institute for Food Safety and Health

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 oktober 2013

Primärt slutförande (Faktisk)

1 augusti 2014

Avslutad studie (Faktisk)

30 augusti 2014

Studieregistreringsdatum

Först inskickad

21 november 2013

Först inskickad som uppfyllde QC-kriterierna

25 november 2013

Första postat (Uppskatta)

26 november 2013

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

27 juli 2021

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

26 juli 2021

Senast verifierad

1 juli 2020

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 2013-114

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Polyphenolic Compounds and Metabolism

  • Children's Hospital of Philadelphia
    Eli Lilly and Company; University of Pennsylvania; Takeda; National Institute... och andra samarbetspartners
    Rekrytering
    Myelin Disorders Biorepository Project (MDBP)
    Mukopolysackaridoser | Leukoencefalopati | Leukodystrofi | Adrenoleukodystrofi | Adrenomyeloneuropati | X-länkad adrenoleukodystrofi | Gangliosidoser | Metakromatisk leukodystrofi | Krabbes sjukdom | Refsums sjukdom | Cadasil | Sjögren-Larssons syndrom | Allan-Herndon-Dudleys syndrom | Vitsubstanssjukdom | GM2 Gangliosidos och andra villkor
    Förenta staterna
  • Children's Hospital of Philadelphia
    Illumina, Inc.
    Aktiv, inte rekryterande
    LeukoSEQ: Helgenomsekvensering som ett första linjens diagnostiskt verktyg för leukodystrofier
    Mukopolysackaridoser | Leukodystrofi | Adrenoleukodystrofi | Adrenomyeloneuropati | X-länkad adrenoleukodystrofi | Gangliosidoser | Metakromatisk leukodystrofi | Krabbes sjukdom | Refsums sjukdom | Cadasil | Sjögren-Larssons syndrom | Allan-Herndon-Dudleys syndrom | Vitsubstanssjukdom | GM2 Gangliosidos | Zellwegers syndrom och andra villkor
    Förenta staterna
  • RTI International
    Eunice Kennedy Shriver National Institute of Child Health and Human Development... och andra samarbetspartners
    Anmälan via inbjudan
    Tidig kontroll: utökad screening hos nyfödda
    Primär hyperoxaluri typ 3 | Diabetes mellitus | Blödarsjuka A | Hemofili B | Ärftlig fruktosintolerans | Cystisk fibros | Faktor VII-brist | Fenylketonuri | Sicklecellanemi | Dravets syndrom | Duchennes muskeldystrofi | Prader-Willis syndrom | Fragilt X-syndrom | Kronisk granulomatös sjukdom | Retts syndrom | Wilsons sjukdom | Niemann-Pick sjukdom, typ... och andra villkor
    Förenta staterna

Kliniska prövningar på Active Capsule

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Panama

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera